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RESOURCE ARTICLE

A multidimensional metabolomics workflow to image
biodistribution and evaluate pharmacodynamics in adult zebrafish

ABSTRACT
An integrated evaluation of the tissue distribution and
pharmacodynamic properties of a therapeutic is essential for
successful translation to the clinic. To date, however, cost-effective
methods to measure these parameters at the systems level in
model organisms are lacking. Here, we introduce a multidimensional
workflow to evaluate drug activity that combines mass spectrometrybased imaging, absolute drug quantitation across different biological
matrices, in vivo isotope tracing and global metabolome analysis in
the adult zebrafish. As a proof of concept, we quantitatively
determined the whole-body distribution of the anti-rheumatic agent
hydroxychloroquine sulfate (HCQ) and measured the systemic
metabolic impacts of drug treatment. We found that HCQ distributed
to most organs in the adult zebrafish 24 h after addition of the drug to
water, with the highest accumulation of both the drug and its
metabolites being in the liver, intestine and kidney. Interestingly,
HCQ treatment induced organ-specific alterations in metabolism.
In the brain, for example, HCQ uniquely elevated pyruvate
carboxylase activity to support increased synthesis of the neuronal
metabolite, N-acetylaspartate. Taken together, this work validates a
multidimensional metabolomics platform for evaluating the mode
of action of a drug and its potential off-target effects in the adult
zebrafish.
This article has an associated First Person interview with the first
author of the paper.
KEY WORDS: Zebrafish, Metabolomics, Pharmacodynamics, Mass
spectrometry imaging, Drug discovery

INTRODUCTION

The majority of therapeutics evaluated in preclinical testing fail,
making drug development a high-risk and expensive process
(Hay et al., 2014). Compounds that do advance to the clinic
must accumulate at the sites of disease, engage their target,
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and demonstrate acceptable toxicity profiles. Commonly used
models to evaluate the toxicity and efficacy of drug candidates in
the preclinical phase include tissue-culture systems and mouse
models. Of note, these systems have the drawbacks of failing
to recapitulate complex physiology and potentially being cost
prohibitive, respectively. An alternative model is the adult zebrafish,
which shares approximately 70% gene homology with humans, is
cost effective to maintain, can be bred in large numbers, and has a
rapid maturation time (Spitsbergen and Kent, 2003; Howe et al.,
2013; Truong et al., 2014; Cassar et al., 2020). An advantage of
using zebrafish over other vertebrate model organisms is the
simplicity of the route in which drugs can be introduced to study
biodistribution and pharmacodynamics. Water-soluble chemicals
can be added directly to the aquarium to enable uptake by the
mouth, skin and gills (Dang et al., 2016). Although less frequently
employed than embryos, adult zebrafish are of particular relevance
to drug studies because individual organs can be dissected and
subsequently evaluated by liquid chromatography/mass spectrometry
(LC/MS) (Jia et al., 2018; Naser et al., 2021; Patton et al., 2021).
Additionally, technologies to genetically modify adult animals,
such as transgene electroporation in adult zebrafish (Callahan et al.,
2018) and morpholino-mediated gene knockdown (Craig et al.,
2010), are available for functional validation of drug targets.
Quantitative analysis of small molecules by mass spectrometry
is broadly referred to as the field of metabolomics (Cajka
and Fiehn, 2016). Depending upon the objectives of an
experiment, metabolomics can be performed by using one or
more complementary approaches. In untargeted metabolomics,
researchers aim to profile small molecules of both endogenous and
xenobiotic origin at the comprehensive scale. Although a global
assessment of metabolism might reveal unexpected biochemical
changes that provide mechanistic insight related to drug activity,
untargeted metabolomics typically only reveals alterations in the
relative levels of compounds. To determine the absolute
concentration of a drug compound or metabolite, investigators
generally rely on an experimental paradigm known as targeted
metabolomics (Schwaiger-Haber et al., 2021). In these analyses, a
selected set of reference chemicals are spiked into each biological
matrix at known concentrations to correct for differences in
ionization efficiencies. It is important to point out that both
untargeted and targeted metabolomics have limitations for
evaluating drug activity and biodistribution. First, most untargeted
and targeted metabolomics experiments are label free and provide
only a snapshot of metabolism. To capture pathway dynamics,
isotopically labeled tracers must be introduced into the biological
system and their transformation monitored (Zamboni et al., 2015).
Second, the most commonly used technology for performing
untargeted and targeted metabolomics is LC/MS, which is
performed on homogenized tissues and, therefore, does not
provide information about the anatomical location of compounds.
1
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To map the spatial distribution of small molecules, a metaboliteimaging approach is required, such as matrix-assisted laser
desorption/ionization (MALDI) or desorption electrospray
ionization (DESI) (Rubakhin et al., 2005; Eberlin et al., 2011).
In this study, we developed a multidimensional platform that
integrates untargeted metabolomics, absolute drug quantitation,
in vivo isotope tracing and mass spectrometry-based imaging to
examine the biodistribution and pharmacodynamics of
hydroxychloroquine sulfate (HCQ) in adult zebrafish. An advantage
of using adult zebrafish for such an analysis is that isotope tracers can
be easily administered to animals by simply adding them to the tank
water. Additionally, the size of the adult zebrafish is uniquely suited
for biodistribution studies because a cross-section of the entire animal
can be readily analyzed by MALDI or DESI imaging in a single
experiment at a resolution that enables visualization of metabolic
organs. Originally developed as an antimalarial in the drug class of 4aminoquinolines, HCQ has been prescribed for long-term use in
rheumatic diseases, including rheumatoid arthritis and systemic lupus
erythematosus (Browning, 2014; Schrezenmeier and Dörner, 2020).
HCQ has pleiotropic actions in vivo that have complicated our
understanding of its mechanism of action and optimal dosing (Fox,
1993; Nirk et al., 2020; Schrezenmeier and Dörner, 2020). Here, by
imaging HCQ accumulation in animals, we show that differential
uptake of the drug in organs contributes to unique alterations in
metabolism. We further demonstrate that, despite accumulating at low
concentrations in the brain, HCQ increases pyruvate carboxylase
activity to support elevated synthesis of N-acetylaspartate, a marker of
neuronal integrity (Moffett et al., 2007). Taken together, these results
validate a multidimensional workflow in adult zebrafish to obtain
quantitative information on drug distribution, in addition to systemslevel profiling of drug activity and toxicity for efficient preclinical
evaluation of drugs.

At concentrations of HCQ above 2.5 mM, we observed
considerable mortality. When treating WT animals with 1 mM
HCQ for 24 h, however, no animal death occurred (Fig. 1A). Using
this concentration of 1 mM, we next monitored the kinetics of HCQ
accumulation within the adult zebrafish. We placed fish in 1 mM
HCQ for 12, 24 and 48 h, and then monitored the relative
concentration of HCQ in various tissues compared to that in the
liver, which is a well-characterized site of HCQ accumulation and
metabolism (Schrezenmeier and Dörner, 2020). Steady-state drug
concentrations were reached by 24 h for all tissues tested (Fig. 1B).
These data indicate that this drug concentration and exposure time
are appropriate for steady-state metabolomic studies.

We first explored the toxicity profile of HCQ in wild-type (WT)
adult zebrafish. Fish were placed in concentrations of HCQ that
ranged from 1 µM to 10 mM and survival was monitored over time.
Similar to embryos, adult zebrafish take up drugs dissolved in their
tank water (Dang et al., 2016; Jia et al., 2018; Cassar et al., 2020).

LC/MS necessitates that samples be homogenized prior to analysis
and, therefore, it does not provide information about tissue
heterogeneity or the spatial distribution of chemicals. Unlike
LC/MS, mass spectrometry-based imaging techniques such as
DESI can be applied to intact sections of tissue. Accordingly, a
single DESI imaging experiment can provide a map of drug
distribution across the entire zebrafish animal. We applied DESI
imaging to adult fish treated with 1.5 mM of HCQ for 24 h to
determine the sites of drug accumulation and metabolism. Untreated
animals were used as controls to assess potential background
signals. After euthanizing the fish and amputating their caudal fin,
the animals were exsanguinated to remove interference from HCQ
and its metabolites in blood prior to imaging.
DESI imaging of drug-treated zebrafish showed localization of
HCQ in three primary organs. The liver and intestine had high
uptake of HCQ and accumulated its primary metabolites,
desethylhydroxychloroquine and desethylchloroquine (Fig. 2;
Fig. S1A,B). This result is in line with the degradation of
4-aminoquinolines by the cytochrome P450 enzymes, CYP2C8
and CYP3A4, both present in the gastrointestinal tract and liver in
humans (Dresser et al., 2000; Enayetallah et al., 2004). Liver and
intestinal tissues from adult zebrafish are known to express
cyp3a65, which has 54% similarity to human CYP3A4 (Tseng
et al., 2005; Goldstone et al., 2010). The kidney was the third organ
that showed high signals from HCQ and related metabolites,
indicating that renal clearance as a mechanism for drug elimination

Fig. 1. Toxicity and biodistribution of HCQ in adult zebrafish. (A) Toxicology profile for adult sjA zebrafish treated with HCQ. Survival is plotted as a function of
exposure time (h); n=10 fish per group. (B) Accumulation of HCQ in serum and organs (relative to liver 24 h samples) after 1 mM HCQ treatment for 24 h. These
data demonstrate steady-state conditions at 24 h. Values are mean±s.e.m.; n=3-4 fish per time point. For the 0 h time point, n=3 for liver, and n=4 for serum, brain,
eye, fin, heart and muscle. For the 12 h time point, n=3 for serum, and n=4 for brain, eye, fin, heart, liver and muscle. For the 24 h time point, n=4 for all organs. For
the 48 h time point, n=3 for serum, brain and heart, and n=4 for eye, fin, liver and muscle. Statistical significance was evaluated with a two-tailed, unpaired t-test;
ns, not significant.
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is shared between fish and humans (Browning, 2014). It is notable
that the third primary metabolite of HCQ, bidesethylchloroquine (or
bisdesethylchloroquine), was not detected in any experiments
(neither by DESI imaging nor by LC/MS), likely due to the
relatively low rate of bioconversion (Brown et al., 1986; Browning,
2014). We point out that only low levels of HCQ were detected in
the heart, demonstrating that not all centrally located tissues
accumulated HCQ to the extent that the liver and intestine did. All
fish analyzed by DESI imaging had metabolite signals across the
entire body of the animal, but not in the cavity left by the swim
bladder. This result was best visualized by the total ion current
(TIC), which is the sum of all signals detected. As expected,
metabolites were concentrated in major organs such as the brain and
heart in addition to the liver, intestine and kidney. Additionally,
when HCQ images were scaled to the TIC, the patterns of
localization remained similar to non-normalized data (Fig. S1C),
corroborating that HCQ accumulation in the intestine, liver and
kidney was not due to signal intensity fluctuations across the fish.
These data provide confirmation that the DESI imaging platform is
well suited for the measurement of exogenous drugs as well as
endogenous metabolites in the adult zebrafish.
Absolute quantitation of drug across tissues using a
matrix-matched calibration curve

The activity of a drug is dependent on both its accumulation in the
appropriate organ and binding to the desired protein target

(Ijzerman and Guo, 2019; An, 2020). Therefore, quantitative
assessment of drug concentrations within an organism is needed to
properly interpret drug efficacy. Although DESI imaging can reveal
the relative levels of a given drug throughout the body of a zebrafish,
measuring the absolute concentration of the chemical across
different tissues is best accomplished by performing targeted
metabolomics with LC/MS. Unlike DESI imaging, LC/MS does not
require tissue sectioning and, therefore, avoids potential problems
such as signal distortions around tissue edges. The general practice
when using LC/MS for quantitation is to create a calibration curve
for each biological matrix (Dahal et al., 2011; Loos et al., 2016). In
our case, we spiked different concentrations of the drug (together
with a labeled version of the drug at a single concentration as an
internal standard) into metabolic extracts from each zebrafish organ.
It is important that the organs were obtained from animals that had
not been administered HCQ, so that the only source of the drug was
from the spike in. The purpose of creating a calibration curve for
organs was to account for differences in drug ionization that result
due to the presence of unique biological matrices (Fig. S2A).
A major limitation of creating calibration curves for each organ in
the zebrafish is the resources and time required. In this particular
study in which we aimed to quantitate drug concentrations
throughout the animal, it required doing experiments with seven
sets of individual tissues. Altogether we evaluated five
concentrations of the drug in triplicate for each tissue, amounting
to 105 LC/MS injections (Table S1). As an alternative, we
3
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Fig. 2. DESI-MS imaging localizes
HCQ and its metabolites to specific
organs in zebrafish. Annotated
reference photographs (top) for
collected sections of representative
HCQ-treated (1.5 mM, 24 h) and
control (no treatment) zebrafish. HCQ
and its metabolites,
desethylhydroxychloroquine and
desethylchloroquine, were detected in
high abundance (compared to control
tissue), with enrichment in the intestine,
liver and kidney. Comparable intensity
in total ion current (TIC, described in
Materials and Methods) confirmed
stable DESI performance. Figures are
representative images from a single
section of each fish. n=2 per group (see
Fig. S1B for replicate images). Scale
bars: 1 cm.

RESOURCE ARTICLE

Disease Models & Mechanisms (2022) 15, dmm049550. doi:10.1242/dmm.049550

considered the possibility of using a single calibration curve from a
pooled set of tissues to quantitate drug concentrations across the
entire zebrafish. To that end, we mixed intestine, liver, heart, eye,
muscle, fin and brain tissue from animals that had not been treated
with the drug. We then spiked in the drug at different known
concentrations to create a single calibration curve, which we
subsequently used to quantitate drug concentrations in all tissues
analyzed. Using a single calibration curve from pooled tissues
reduced the number of LC/MS injections from 105 to 15, but the
drug concentrations determined were not significantly different
from when we used tissue-specific calibration curves (Fig. S2B).
The linear equations for each method are provided in Table S1, all of
which showed high correlation coefficients (r>0.998). Our results
demonstrate that using pooled tissues to approximate the biological
matrix for quantitation is an efficient and accurate way to streamline
drug-biodistribution studies.
Absolute quantitation data from targeted LC/MS analyses
corroborated the general localization patterns observed from DESI
imaging (Fig. S2C). HCQ accumulated in the liver and intestine at
more than three times its concentration in other organs (Fig. 3A),
which is consistent with the known roles of the liver and intestine in
metabolism (Pond and Tozer, 1984). These findings indicate that
the distribution of HCQ is similar between zebrafish and humans,
highlighting the utility of this organism as a model system for
pharmacokinetic analysis (Costedoat-Chalumeau et al., 2020).
Additionally, with LC/MS, we were able to quantitate the
absolute concentration of HCQ in the serum of individual adult
zebrafish. To collect a sufficient amount of material while
minimizing perturbations to metabolism, we used low-speed
centrifugation to collect blood from the amputated caudal fin of
anesthetized animals. We have previously shown that this strategy
for obtaining blood from adult zebrafish is more efficient than direct
pipetting methods (Naser et al., 2021).

guidelines suggested by the Metabolomics Standards Initiative
(Sumner et al., 2007; Stancliffe et al., 2021). We found that HCQ
treatment uniquely decreased the levels of some amino acids in the
heart. In contrast, both the liver and kidney showed general increases
in nitrogen-containing small molecules such as amino acids and
nucleotides. In addition, the liver also showed alterations in the
tricarboxylic acid (TCA) cycle intermediates citrate and cis-aconitate.
One striking alteration that we only observed in the brain was related
to N-acetylaspartate (NAA). Although the brain accumulated the
lowest amount of HCQ, a statistically significant increase in NAA
levels was measured (Fig. 3C, Fig. 4A). These data are consistent
with organ-specific regulation of metabolism in response to drug
treatment.

We next sought to identify HCQ-related changes in metabolism that
could be linked to either drug efficacy or toxicity. Organs from
zebrafish exposed to 1 mM HCQ for 24 h were compared to organs
from untreated animals by LC/MS-based untargeted metabolomics.
We also performed LC/MS experiments on blank controls that did
not contain any zebrafish specimens to annotate background ions
originating from non-biological sources. Using the computational
strategies that we established before, zebrafish datasets were
processed to remove contaminants and degeneracies such as salt
adducts (Mahieu and Patti, 2017; Cho et al., 2021). The signals that
remained after filtering represented unique metabolites that are of
physiological relevance. Surprisingly, the number of metabolites
with statistically significant alterations in each organ did not
correspond to the concentration of the drug in that tissue (Fig. 3B).
The intestine, a site of considerable HCQ accumulation, showed the
most metabolic changes. Muscle, on the other hand, had the second
highest number of metabolite alterations despite its relatively low
uptake of HCQ. Moreover, even though the liver accumulated the
highest concentration of the drug, it had a comparatively small
number of altered metabolites.
Another interesting trend that we observed in the data is that the
same metabolic alterations were not conserved across all tissues. To
gain additional biochemical insight into organ-specific differences,
we identified metabolites that only showed altered levels in particular
tissues. All identifications were supported by matching experimental
data from zebrafish to data obtained from using authentic reference
standards, thereby providing level 1 confidence according to the

NAA is one of the most abundant small molecules in the brain. It is a
general marker of neuronal health (Stovell et al., 2017), participates
in neuron-oligodendrocyte communication (Singhal et al., 2017),
and serves as a biosynthetic precursor to the important
neurotransmitter N-acetylaspartylglutamate (NAAG) (Tsai and
Coyle, 1995; Pouwels and Frahm, 1998; Moffett et al., 2007). We
surmised that the increased levels of NAA that we observed in the
brain of HCQ-treated fish might be supported by increased NAA
biosynthesis. To test this prediction, we conducted an isotopetracing experiment with 13C6-glucose. Adult zebrafish were
randomly transferred to one of two aquariums containing 10 mM
13
C6-glucose for 24 h. We already established in prior work that
these conditions lead to steady-state labeling of glucose in the
circulation of adult zebrafish and pseudo isotopic steady state in
other tissues (Naser et al., 2021). In this work, in addition to 10 mM
13
C6-glucose, one aquarium contained 1 mM HCQ. The other
aquarium contained 10 mM 13C6-glucose but no HCQ as a control.
We used 13C6-glucose as a tracer because it can be transformed
into both precursors of NAA, acetyl-CoA and aspartate (Moffett
et al., 2007). Specifically, there are three routes by which the labeled
carbon atoms can be incorporated into NAA from 13C6-glucose
(Fig. 4B,C). In the first route, 13C6-glucose produces 13C2-acetylCoA, which is directly used to synthesize NAA. In the second route,
glucose-derived 13C2-acetyl-CoA contributes its activated carbon to
the TCA cycle, which subsequently produces labeled oxaloacetate.
Oxaloacetate equilibrates with aspartate, which can be used to
synthesize NAA with two labels (M+2, where M indicates the
mass of the unlabeled metabolite). In the third route, 13C6-glucose is
transformed into 13C3-pyruvate, which then contributes all three of
its labeled carbons to oxaloacetate via pyruvate carboxylase
activity. The third route produces NAA with three labels (M+3).
We also observed NAA containing one label (M+1), which is
synthesized from M+1 aspartate (Fig. 4D) and unlabeled acetylCoA. It has been suggested that when providing animals with 13C6glucose as a tracer, M+1 aspartate might originate from malic
enzyme activity (Sun et al., 2017).
By monitoring the pattern of label incorporation into NAA, we
aimed to assess potential changes in NAA biosynthesis. Notably,
neither M+1 nor M+2 NAA showed any statistically significant
differences between HCQ-treated and control animals. We did find,
however, that M+3 NAA was elevated in animals exposed to the
drug (Fig. 4C). We reasoned that the increase in M+3 NAA was due
to elevated pyruvate carboxylase activity, which provides a source
of carbon for the TCA cycle to replace the oxaloacetate being
removed for NAA biosynthesis. As additional evidence of elevated
pyruvate carboxylase activity in the brain of drug-treated zebrafish,
we found that the level of the M+3 isotopologue of aspartate and
4
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Fig. 3. Systems-level analysis of metabolic alterations reveals tissue-specific differences in metabolism after HCQ treatment. (A) Absolute quantitation of
hydroxychloroquine (HCQ) in organs (μg HCQ/mg tissue) and serum (μg HCQ/ml serum) of zebrafish treated with 1 mM HCQ for 24 h, showing high accumulation
in the liver and intestine. Values are mean±s.e.m.; n=5-8 fish per group. For liver, n=5; for heart and intestine, n=7; for all other organs, n=8. (B) Histogram showing
the count of statistically significant metabolic alterations in organs from HCQ-treated animals relative to untreated controls. Negative-ion mode data shown; n=5-8
fish per group. For control fish, n=5 for kidney and liver; n=6 for brain, eye, fin, heart, intestine and muscle. For HCQ-treated fish, n=7 for muscle and intestine; n=8
for kidney, brain, eye, fin, heart and liver. (C) Heatmap of select metabolites showing a statistically significant difference between HCQ-treated and control
zebrafish. Increases in HCQ-treated animals are shown in red and decreases are shown in blue. Negative- and positive-mode data shown; n=5-8 fish. For control
fish, n=5 for kidney and liver; n=6 for brain, eye, fin, heart, intestine and muscle. For HCQ-treated fish, n=7 for muscle and intestine; n=8 for kidney, brain, eye, fin,
heart and liver. Statistical significance was evaluated with a one-way ANOVA with Tukey’s method at 95% confidence (A) and with a two-tailed, unpaired t-test (C).
ns, not significant; ****P<0.0001.

several other TCA cycle intermediates were increased (Fig. 4D;
Fig. S3A,B). We point out that no other tissues showed similar
labeling patterns indicative of elevated pyruvate carboxylase
activity, except the eye (Fig. 4D; Fig. S3C). We conclude that the
contribution that the third route provides to NAA is increased
relative to the first and second routes in the brain and eye tissue of
HCQ-treated fish.
DISCUSSION

Most drug-discovery workflows using zebrafish are based on
screening embryos, which have many attractive characteristics
relative to other model organisms, as has been comprehensively
reviewed previously (Scholz, 2013). When studying metabolism,

however, the adult zebrafish has a key technical advantage over
embryos in that its size enables metabolic analysis of organs and
blood from individual animals by mass spectrometry (Naser et al.,
2021). Similar to embryos, drugs can be administered to adult
zebrafish by simply dissolving them in aquarium water. Subsequent
metabolomics analysis then allows for the unique characterization
of the pharmacokinetic and pharmacodynamic properties of a
drug. Additionally, comprehensive metabolite profiles generated
from each organ after drug exposure have the potential to provide
new mechanistic insight into the mode of action and toxicity of the
drug.
The main objective of the current work was to establish a
multidimensional platform that exploits recent advances in
5
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Fig. 4. HCQ increases NAA biosynthesis and pyruvate carboxylase activity in the brain. (A) Pool size of NAA in the brain of HCQ-treated fish compared to
untreated controls; n=6-8 fish per group. For control brains, n=6; for HCQ brains, n=8. (B) Labeling diagram to show three routes for glucose carbon to contribute to
NAA biosynthesis. Pyruvate carboxylase, PC. (C) Fractional labeling (relative to serum M+6 glucose) of NAA in brain tissue of HCQ-treated zebrafish versus
controls; n=6-9 fish per group. For control brains, n=6; for HCQ brains, n=9. (D) Fractional labeling of aspartate from 13C6-glucose in HCQ-treated and control
zebrafish; n=6-9 fish per group. For control fish, n=6 for brain; n=8 for eye, fin, heart, liver and muscle. For HCQ-treated fish, n=8 for heart and liver; n=9 for brain,
eye, fin and muscle. An expanded plot is shown in Fig. S3A. Statistical significance was evaluated with a two-tailed, unpaired t-test. ns, not significant; *P<0.05;
**P<0.01.

metabolomics technologies to study drug activity at a
comprehensive level in the adult zebrafish. We focused on
combining four mass spectrometry-based approaches, providing
highly complementary information that is critical in the process of
drug discovery and development. We used HCQ as a proof of
principle here, but the workflow we describe is broadly applicable to
any compound that is water soluble. First, we mapped the
distribution of HCQ across the entire zebrafish by using in situ
metabolite imaging. The DESI imaging approach we applied has
several important benefits. Unlike some other commonly used mass

spectrometry-based imaging techniques, it does not require the
addition of a matrix and, therefore, avoids background signals that
potentially interfere with small-molecule drug detection (Guo et al.,
2002; Patti et al., 2010). Second, by imaging longitudinal sections
of animals, we were able to monitor drug accumulation in organs
that are challenging to dissect for LC/MS analysis, such as the
pancreas (Arjmand et al., 2020). In contrast to LC/MS experiments
in which an entire organ is homogenized prior to analysis, DESI
imaging also allows different functional areas of a tissue to be
spatially resolved. The disadvantage of DESI imaging is that it only
6
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allows for semi-quantitative analysis of drug levels. To determine
absolute drug concentrations, we integrated a targeted
metabolomics approach that relies on creating a calibration curve
with an authentic reference standard. Although it is general practice
to create a calibration curve for each biological matrix evaluated, in
this case, each organ, the process is time consuming and resource
intensive. Thus, as an alternative, we explored the possibility of
using one calibration curve from a set of pooled zebrafish tissues.
We validated that this higher-throughput method did indeed have
comparable quantitative accuracy relative to organ-specific
calibrations. To complement analyses of drug levels, we applied a
third experimental strategy known as untargeted metabolomics in
which metabolites are profiled from individual zebrafish tissues
at the global scale. Untargeted metabolomics can be applied
not only to examine known mechanisms, but also to discover
metabolic alterations associated with unexpected drug activities.
Notwithstanding, untargeted metabolomics evaluates the relative
differences in metabolite levels, which only provides a static
snapshot of metabolism. To gain additional knowledge about the
dynamics of metabolic pathways after drug treatment, we integrated
a fourth technique into our workflow, which monitors the fate of an
isotopically labeled tracer. Zebrafish are particularly well suited to
study drug activity by using isotope-tracer analysis as the labeled
nutrient can be added directly to tank water with the drug (Naser
et al., 2021). Together, this combination of advanced metabolomics
technologies provides an unprecedented level of resolution to study
drug activity in adult zebrafish.
A unique characteristic of our platform is that we can measure
metabolic processes from each major organ in a single set of
experiments. For our proof-of-principle work, this led to the
interesting observation that HCQ induces unique metabolic changes
in different tissues. It is intriguing to consider why a drug might
have organ-specific effects. One possibility is that the drug
accumulates at different levels throughout the animal, thereby
having varying degrees of activity and perhaps engaging unique
targets at higher concentrations (Yao et al., 2020). Another
possibility is that different tissues exhibit alternative degrees of
metabolic flexibility (Galgani and Fernández-Verdejo, 2021). Some
cell types might be highly sensitive to blocking a biochemical
pathway, for example, whereas others might have compensatory
mechanisms in place to overcome metabolic inhibition. It is also
conceivable that the pathway targeted by a drug might not be active
or required for all organs to function, or that chemical inhibition in
one tissue changes physiological interactions between other tissues.
To date, these sorts of chemical mechanisms have been challenging
to study, owing to a paucity of techniques for comprehensively
assessing how metabolism changes within each organ upon drug
treatment. The workflow that we have established here for the adult
zebrafish helps address this gap by simultaneously surveying
metabolism at both the organ and systemic levels in a single
set of experiments. In our proof-of-principle study, we found
that HCQ and its major metabolites (desethylchloroquine and
desethylhydroxychloroquine) were concentrated in the liver,
intestine and kidney. Our findings indicate that these organs are
the major sites of HCQ accumulation and metabolism in zebrafish,
which is consistent with drug distribution data from mice (Chhonker
et al., 2018), cynomolgus macaques (Liu et al., 2021) and humans
(Van Eaton and Gustafson, 2021). Interestingly, the levels of HCQ
accumulation did not correlate with the magnitude of metabolic
changes. As an example, we observed a high level of metabolic
dysregulation in the muscle, where HCQ levels were relatively low
compared to those in the liver and intestine. Several mechanisms of

action have been proposed for HCQ, including inhibition of
autophagy and suppression of inflammatory cytokine release (Gies
et al., 2020). Although the exact relationship between these
processes and our metabolic changes remains to be defined, we
observed several interesting organ-specific metabolic signatures in
HCQ-treated zebrafish. The kidney showed increases in the
renoprotective molecules acetylcarnitine and glycine (Wang et al.,
2018), which might play a role in the mitigation of lupus-induced
kidney injury by HCQ (Gómez-Guzmán et al., 2014). In contrast to
its protective role in the kidney, HCQ can induce oxidative stress in
muscle, leading to drug-induced myopathy (Uzar et al., 2012). We
observed significant decreases in the levels of metabolites in
muscle, including the redox-associated metabolites NADP+, serine
and methionine. Moreover, although the brain had low amounts of
HCQ, the brain and eye were unique in that they had increased
pyruvate carboxylase activity. This metabolic adaptation might be
related to distinct biochemical processes that are specific to the
nervous system, such as production of neurotransmitters.
Predicting drug efficacy and toxicity in the preclinical stage
remains one of the most challenging problems in drug development.
Adult zebrafish have previously been used to screen for specific
pathologies such as drug-induced kidney injury (Kato et al., 2020),
inhibitors of fin regeneration (Oppedal and Goldsmith, 2010) and
new chemotherapeutics (Nguyen et al., 2012). The workflow
introduced here will augment this prior work that utilized
phenotypic screens by providing a systems-level view of drug
activity, therapeutic outcomes and toxicity at the metabolic level
throughout the entire animal.
MATERIALS AND METHODS
Reagents

All solvents and reagents used for metabolite extraction and analysis
by LC/MS and DESI imaging were of LC/MS grade. Acetonitrile, methanol
and water were purchased from Honeywell (Charlotte, NC, USA), and
ammonium bicarbonate, methylenediphosphonic (medronic) acid,
ammonium hydroxide and formic acid were purchased from SigmaAldrich. The sodium carboxymethylcellulose (CMC) used for preparing
zebrafish for DESI imaging was purchased from Sigma-Aldrich.
Hydroxychloroquine sulfate was pharmaceutical grade and purchased
from Sigma-Aldrich, 13C6-glucose was purchased from Cambridge
Isotopes (Tewksbury, MA, USA), and penicillin-streptomycin was
purchased from Life Technologies (Carlsbad, CA, USA). The labeled
HCQ-D4 internal standard used for absolute quantitation was purchased
from Cayman Chemical (Ann Arbor, MI, USA).

Use of animals in this study was conducted in accordance with the
Washington University Institutional Animal Care and Use Committee
regulations. All zebrafish were in-bred AB strain (sjA) and were reared by
using standard practices (Nechiporuk et al., 1999; Westerfield, 2000). Fish
were maintained at a temperature of 28±1°C under a 14:10 hr light:dark
circadian cycle. All experiments were performed by using adult, agematched, randomly selected male and female zebrafish, except for DESI
imaging. DESI-imaging experiments utilized only males for anatomical
consistency in slicing and spatial distribution. Prior to use in experiments,
fish were fasted for 24 h to clear the intestine. Treatments were conducted in
washed, autoclaved beakers with conditioned facility water, in which the
fish were allowed to swim freely. All experiments were conducted at a
consistent density, no greater than one fish per 100 ml water. During all
treatments, beakers were maintained under the same pre-experimental
conditions (temperature, light cycle) by using a heated water bath and timed
lighting. Sample sizes for individual experiments are provided in their
corresponding figure legends.
Zebrafish were anesthetized and euthanized by using gradual cooling
to minimize perturbations to blood glucose due to chemical anesthesia
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(Eames et al., 2010; Naser et al., 2021). For anesthesia, zebrafish were
placed in a beaker with 100 ml facility water at 17°C. The beaker was placed
in a shallow ice bath and the temperature was lowered over the course of
approximately 5 min to 12°C, when stage 3, phase 2 anesthesia was reached.
For euthanasia, zebrafish were placed in a beaker with 100 ml facility water
and ice for at least 10 min. Euthanasia was deemed complete 1 min after the
cessation of opercular movements.

serum extract from all fish. The HCQ-D4 internal standard was added to the
pooled extracts at 1 µg/ml. Using this matrix, HCQ (unlabeled solid) was
dissolved and serially diluted (1:10) to produce two calibration curves, one
for serum and one for organs, each consisting of five concentration points
ranging from 10 ng/ml to 100 µg/ml HCQ in 100 µl extract. Each calibration
curve was handled identically to its corresponding samples to be quantified
(organs or serum), being carried through the same extraction process and
analyzed simultaneously by LC/MS.
For absolute quantitation in treated animals, adult zebrafish were placed in
1 mM HCQ for 24 h. At the end of the experiment, fish were euthanized and
organs were harvested and snap frozen. Metabolite extraction in tissues and
serum was carried out by using methods identical to those described above,
with the addition of 1 µg/ml HCQ-D4 added directly to the 2:2:1 methanol:
acetonitrile:water solvent as an internal standard.

For initial survival-curve data, adult zebrafish (n=3 per group) were placed
in treated facility water containing 2% penicillin/streptomycin as well as
concentrations of HCQ ranging from 1 µM to 10 mM. Survival was
documented every 24 h, and non-surviving fish were immediately removed.
Once drug tolerance was gauged with the pilot study, the experiment was
repeated and expanded to include larger sample sizes (n=10 animals per
group) and more intermediate concentrations.
For initial pharmacokinetic plots, adult zebrafish were placed in treated
facility water containing 2% penicillin/streptomycin as well as 1 mM HCQ
for up to 48 h. Fish were euthanized, their organs harvested, and HCQ levels
analyzed at 0, 12, 24 and 48 h of exposure. For all further LC/MS
experiments, adult zebrafish were placed in treated facility water containing
2% penicillin/streptomycin (to prevent bacterial growth). Drug-treated
groups were administered 1 mM HCQ for 24 h.
For all experiments, n-values are listed in the figure legends. For some
experiments, tissues have different n-values. This difference in n-values
between tissues is because we were unable to successfully harvest each
tissue from all animals. We also point out that not every experiment used the
same number of animals. This is because some fish died during experiments
and were not included in the study.
Serum and tissue harvest and extraction

Serum and tissues were harvested and extracted from zebrafish as previously
described (Naser et al., 2021). Briefly, fish were euthanized by using gradual
cooling and thoroughly dried before caudal fin amputation for blood
collection. Fish were immediately transferred (wound side down) to a bloodcollection device consisting of one 1.5 ml microcentrifuge tube (holding
tube) with a small (∼0.5 mm) hole in the bottom attached to a 0.5 ml
microcentrifuge tube (collection tube). Zebrafish were centrifuged at 40 g
for 1 min at 15°C. The collected blood was placed on ice for 10 min to clot.
During this time, organs were dissected from the fish, placed in pre-weighed
1.5 ml microcentrifuge tubes, and snap frozen in liquid nitrogen. After
10 min, the blood was centrifuged at 1600 g for 10 min at 4°C. Immediately,
the serum was pipetted into a new 0.5 ml microcentrifuge tube and snap
frozen in liquid nitrogen. All samples were stored at −80°C until extraction.
For metabolite extraction, tissue samples were ground to a powder in
liquid nitrogen by using a disposable plastic pestle. Tissue samples were
immediately weighed and a normalized volume of 40 µl of 2:2:1 methanol:
acetonitrile:water per 1 mg tissue was added. Samples were vortexed, snap
frozen, and stored at −80°C. At the same time, all tissue samples were
extracted by using the following sequence: thawing in a room-temperature
water bath, sonication at room temperature for 5 min, vortexing, snap
freezing in liquid nitrogen, thawing in a room-temperature water bath,
sonication at room temperature for 5 min, vortexing, and incubation for 1 h
at −20°C. After incubation, samples were centrifuged at 20,000 g for 10 min
at 4°C. Supernatants were transferred to LC/MS vials for analysis.
Metabolite extraction of serum samples was completed by using a
different method from tissue samples. Serum samples were thawed on ice
and diluted 1:15 in 2:2:1 methanol:acetonitrile:water. Samples were mixed
and incubated at −20°C for 1 h. After incubation, samples were centrifuged
at 20,000 g for 10 min at 4° C. Supernatants were transferred to LC/MS vials
for analysis.
Absolute quantitation experiment

To generate calibration curves, untreated control fish were carried through
the organ harvesting and metabolite extraction process to generate tissue and
serum samples for metabolite extraction (in 2:2:1 methanol:acetonitrile:
water). From these extracts, a pool was created containing either an
equal-parts mixture of all organs from all fish, or an equal-parts mixture of

DESI-based imaging

MS imaging experiments utilized three treated (1.5 mM HCQ for 24 h) and
three non-treated control male zebrafish. Immediately after treatment, fish
were euthanized, a portion of the tail was excised and each fish was
centrifuged for 1 min at 40 g for blood collection, as described above. Fish
were transported on dry ice, embedded in 5% sodium CMC in water as a
stabilizing matrix, and stored at −80°C. Fish were sectioned at 20 µm
thickness by using a CM 1860 Cryostat (Leica Biosystems). The CMC
matrix was injected into the swim bladders once exposed by the cryostat and
allowed to freeze completely to mechanically stabilize tissue. Sections were
thaw-mounted to Superfrost Plus Glass Slides (Thermo Fisher Scientific).
Slides were cleaned with methanol immediately before use. Collected
sections were dried under vacuum and stored at −80°C. Sections used for
imaging were thawed under vacuum to limit tissue rehydration.
DESI imaging was performed by using a Synapt XS quadrupole time-offlight mass spectrometer with a traveling wave ion mobility cell and a DESIMSI source (Waters Corporation, Milford, MA, USA). Imaging was
performed by using 4.0 kV capillary voltage in negative polarity for
Resolution Mode. DESI spray used 95:5 methanol:water with 0.1% formic
acid and 200 pg/µl leucine enkephalin (Waters Corporation) at a 2.5 µl/min
flow rate, 70° incident angle and −7° collection angle. Images were
collected at a 25 µm/s raster rate for 150 µm×150 µm pixel size. At least two
serial sections were imaged for each fish.
The total ion current (TIC) was collected for each section of the fish, and
relevant mass-to-charge ratios (m/z) were extracted. For non-normalized
images, the values are given as relative intensities. For normalized images
(Fig. S1C), the intensities of the extracted m/z values for each pixel are
divided by the TIC for the same pixel.
LC/MS analysis

All LC/MS analyses in this work were conducted by using a Q Exactive
Plus mass spectrometer coupled to a Dionex Ultimate UHPLC system
(Thermo Fisher Scientific). Chromatographic separation was performed
by hydrophilic interaction liquid chromatography (HILIC) on the
iHILIC-(P) Classic column (100 mm×2.1 mm, 5 µm) (HILICON, Umeå,
Sweden) preceded by a corresponding iHILIC-(P) Classic guard
column (20 mm×2.1 mm, 5 µm). Mobile-phase solvent A was 95:5 water:
acetonitrile (ACN) with 20 mM ammonium bicarbonate, 0.1% ammonium
hydroxide and 2.5 µM medronic acid, and solvent B was 95:5 ACN:water
with 2.5 µM medronic acid. Samples were separated at 0.25 ml/min over a
14 min analysis frame with a 12 min linear gradient, as follows: 0-1 min,
held at 90% solvent B; 1-13 min, ramped 90% to 30% solvent B; 13-14 min,
held at 30% solvent B. Following scanning, the column was flushed at 90%
solvent B for 5 min at an increased flow rate (0.4 ml/min) to ensure
equilibration before the next injection, prior to which the flow rate was
returned to 0.25 ml/min. The injection volume was 3 µl. Before and after
each injection, the needle was washed with 100 µl 1:1 water:ACN. Analysis
sequences were organized with samples in a randomized order consisting of
blocks of ten separated by a solvent blank (2:2:1 methanol:acetonitrile:
water) and a pooled quality control (QC) sample . Three solvent blanks were
run both at the beginning and end of the sequence. For absolute quantitation,
calibration curves were analyzed in triplicate with their corresponding
quantitated samples. All analyses, except for HCQ absolute quantitation,
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were performed in full-scan mode with a scan range of 65-950 m/z, 70 K
resolution (140 K for isotope labeling), maximum ion time of 100 ms and
automatic gain control (AGC) target of 106. Absolute quantitation was
performed by using a targeted single-ion monitoring method selecting for
HCQ and its labeled internal standard (HCQ-D4) with an isolation window
of 2 m/z, 35 K resolution, maximum ion time of 75 ms and AGC target 105.
MS source settings were identical for all analyses, as follows: spray voltage,
−3 kV; sheath gas flow rate, 50; auxiliary gas flow rate, 10; sweep gas flow
rate, 1; S-lens RF level, 30%; capillary temperature, 300°C; and auxiliary
gas heater temperature, 350°C.
Analytical performance and reproducibility for untargeted and isotopelabeling experiments were evaluated by examining peak area ratios of a
panel of known metabolites in the pooled QC sample, all of which showed
relative standard deviations (RSDs) <15% across the analysis, indicating
high reproducibility. For absolute quantitation, the HCQ-D4 internal
standard peak area was used for QC, which showed intra-group
RSD<15% for all organs and serum. Performance of the calibration
curves for organs and serum (triplicate data for each combined into a single
curve for quantitation) was assessed by overall linearity, accuracy and
reproducibility of each calibrator point. Both calibration curves were found
to show excellent linearity (R2>0.999), accuracy and reproducibility
(RSD<10%).

(Waters Corporation) to perform peak picking and lockmass correction
against leucine enkephalin. Images were prepared from processed files by
using a custom Python script and ImageJ. Outliers were calculated by the
Grubbs’ Test with α at 0.05. Metabolomics data are available in Table S2.

Kidney tissue was harvested from adult zebrafish in separate experiments.
Metabolites were extracted and analyzed with LC/MS by using the same
methods as detailed above. The samples were profiled to identify global
changes in metabolism, but absolute quantitation of HCQ in kidney was not
performed. The annotation of kidney as having high accumulation of HCQ
in Fig. 3B is based on relative quantitation as assessed by DESI imaging. We
also note that, for the treatment group, fish were placed in 1 mM HCQ for
24 h prior to harvesting kidney tissue. We assumed that kidney HCQ levels
were at steady state by 24 h. Although this was not formally measured, every
other tissue we examined was at steady state by 24 h (Fig. 1B).
Isotope-tracer experiments

For isotope tracing, 10 mM 13C6-glucose was added to both untreated
control and 1 mM HCQ-treated conditions. Throughout the experiment, fish
were allowed to swim freely. After 24 h, both HCQ levels and isotope
enrichment were at steady state in the fish, and this marked the endpoint of
the experiment. Fish were then euthanized, their organs harvested, and
samples analyzed by LC/MS.
Data processing, statistical analysis and metabolite
identifications

Data processing for this study was performed by using several software,
depending on the specific application. For analysis of the quantitative data,
including peak picking for HCQ or HCQ-D4 and calculation peak area ratios
in samples and calibration curves, Quan Browser (Xcalibur Workstation,
Thermo Fisher Scientific) was used with an optimized processing method.
Data processing for isotope-tracing experiments was performed by using
Skyline ( peak picking) and AccuCor (13C natural-abundance correction)
(MacLean et al., 2010; Su et al., 2017). Data processing of the untargeted
metabolomics data was accomplished by using Compound Discoverer
Version 3 Series (Thermo Fisher Scientific). Statistical significance was
determined by using a two-tailed, unpaired Student’s t-test, except for oneway ANOVA analysis (as labeled in figure legend) using GraphPad Prism
(version 9) with Tukey’s method at 95% confidence. Linear coefficients
were calculated with GraphPad Prism (version 9) by using a two-tailed
Pearson correlation at 95% confidence. All metabolites assigned a
biochemical name were identified at level 1 confidence in accordance
with the Metabolomics Standards Initiative by matching experimental data
from zebrafish to data from authentic reference standards that we generated
in our laboratory by using the specific methods applied in this work (Sumner
et al., 2007; Stancliffe et al., 2021). Identifications were supported by
matching accurate mass measurements (≤10 ppm) and retention times for
LC/MS experiments or ion-mobility drift times for DESI experiments.
DESI-imaging data were processed by using High Definition Imaging
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